SecBot SecBot

SRPT drug pipeline

$16.07
+0.4% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±2.6%
1-day, median of 8 events
IV rank
23
IV 76% · HV 57%
Rated drugs
5
2 mixed · 3 neutral
Phase 3 trials
1
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhaseApproved (Accelerated Approval)
Time to marketAlready on the market under accelerated approval (since February 2021). The sNDA for traditional approval has a PDUFA goal date around April 2027.

AMONDYS 45 casimersen Updated Nov 8

What to watch

Watch for the FDA's decision on the sNDA for traditional approval of AMONDYS 45, expected around April 2027 (standard review timeline from the June 30, 2026 acceptance). Approval would remove the overhang from the failed ESSENCE confirmatory trial and solidify the PMO franchise's revenue stream. Denial could threaten the drug's continued marketing and would be a significant negative for SRPT shares.

Bull case
  • AMONDYS 45 is already approved under accelerated approval (February 2021) and is generating significant revenue as part of Sarepta's PMO franchise, which delivered $240.3M in Q3 2026 net product revenue and drove the company to raise full-year guidance.
  • The FDA accepted the sNDA for traditional approval despite the ESSENCE trial miss, suggesting regulators see a path forward. Sarepta's management has expressed confidence that there is no risk of losing marketing authorization.
  • The drug addresses a clear unmet need for Duchenne muscular dystrophy patients with exon 45 skipping-amenable mutations, a defined genetic subset with few treatment options.
Bear case
  • The Phase 3 ESSENCE confirmatory trial failed to meet its primary endpoint in November 2025, raising fundamental questions about the drug's efficacy. The FDA accepted the sNDA for review despite this failure, but the odds of conversion to traditional approval are uncertain.
  • If the FDA denies the sNDA, the drug's accelerated approval could face withdrawal proceedings, threatening a major portion of Sarepta's revenue stream (the PMO franchise generated $240.3M in Q3 2026).
  • Sarepta faces competitive pressure from Dyne Therapeutics' z-rostudirsen (targeting exon 51), which has a PDUFA date of January 21, 2027 under priority review, potentially eroding the franchise.
● neutral
Impact
PhasePhase 1/2 (MAD - Multiple Ascending Dose)
Time to marketSRP-1003 is in early-stage clinical development (Phase 1/2 MAD study). If the upcoming data supports advancement, a Phase 3 program would follow, meaning regulatory approval and commercialization are likely several years away (estimated 2029-2031 at the earliest).

SRP-1003 Updated Nov 8

What to watch

The next catalyst is the multiple ascending dose (MAD) data readout for SRP-1003 in DM1, expected by year-end 2026 (Q4 2026, within ~2 months). Positive data could support advancement to Phase 3 and re-rate the stock; negative or equivocal data would likely be viewed as a pipeline setback. The data readout is the single most important near-term pipeline catalyst for Sarepta alongside the SRP-1001 (FSHD) readout.

Bull case
  • SRP-1003 targets DM1 (myotonic dystrophy type 1), a serious rare neuromuscular disease with no approved disease-modifying therapies, representing a large unmet need and potential blockbuster opportunity.
  • MAD data readout is imminent (expected Q4 2026, within ~2 months), providing a near-term binary catalyst that could drive significant stock movement.
  • Sarepta has deep expertise in RNA-targeted therapies and a proven commercial infrastructure from its approved Duchenne muscular dystrophy franchise (PMO portfolio generating ~$240M/quarter).
Bear case
  • Early-stage MAD data may not support advancement to Phase 3, as flagged in Sarepta's own risk factors from the Q3 2026 earnings filing.
  • Sarepta has a mixed track record with pipeline candidates beyond its core DMD franchise; DM1 is a biologically challenging indication.
  • Analyst consensus on SRPT is mixed (only 12 of 31 analysts rate it Buy/Strong Buy, with a mean price target of $21.64 implying modest 21% upside), reflecting skepticism about pipeline value.
◆ mixed
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the U.S. for ambulatory Duchenne patients. Expansion to non-ambulatory patients is uncertain after the ENVISION trial closure; a safety study and FDA engagement in Q1 2027 will determine the path forward.

ELEVIDYS delandistrogene moxeparvovec Updated Nov 8

What to watch

Watch for the Q1 2027 FDA engagement on the sirolimus safety study for non-ambulatory patients. A constructive outcome could open a path to label expansion and de-risk the safety narrative, while a negative FDA response would reinforce concerns about ELEVIDYS' risk profile and limit its addressable market. Also monitor quarterly revenue trends for signs of stabilization or further erosion in the approved ambulatory population.

Bull case
  • ELEVIDYS is the only approved gene therapy for Duchenne muscular dystrophy, a large unmet-need market with no cure, giving Sarepta a first-mover advantage.
  • New data from the 2026 World Muscle Society congress showed durable and clinically meaningful functional benefit in older ambulatory patients (ages 8-12) over two years versus external controls, supporting the approved label.
  • Sarepta raised the low end of its 2026 total net product revenue guidance by $50 million to a range of $1.25-$1.3 billion, signaling confidence in the commercial franchise including ELEVIDYS.
Bear case
  • The ENVISION Phase 3 trial in non-ambulatory patients was closed after three patient deaths from acute liver failure, a major safety setback that raises questions about the therapy's risk profile.
  • The FDA added a black-box warning for acute serious liver injury and acute liver failure to the ELEVIDYS label in August 2026, the strongest possible safety warning.
  • In July 2025, the FDA asked Sarepta to voluntarily stop shipping ELEVIDYS; Sarepta refused, and the stock fell 36% in a single day, damaging management credibility with regulators.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed in the U.S. since September 2016.

EXONDYS 51 eteplirsen Updated Nov 8

What to watch

The next major catalyst for EXONDYS 51 is not a regulatory decision on the drug itself (already approved), but the January 21, 2027 PDUFA date for Dyne Therapeutics' competing exon 51 DMD drug z-rostudirsen. An approval would introduce direct competition to EXONDYS 51's core market. Separately, watch for Sarepta's quarterly revenue trends for the exon-skipping franchise and any updates on confirmatory trial data that could convert EXONDYS 51 from accelerated to traditional approval.

Bull case
  • EXONDYS 51 was the first FDA-approved drug for Duchenne muscular dystrophy and remains the only approved therapy for the ~13% of DMD patients amenable to exon 51 skipping, giving it a first-mover advantage and established commercial infrastructure.
  • Sarepta's Q3 2026 earnings highlighted continued strength in its exon-skipping franchise, and the company raised the low end of its 2026 product revenue guidance to $1.25-$1.3 billion, suggesting stable demand for EXONDYS 51 and its sister drugs.
  • Multiple institutional investors added or doubled their SRPT positions in Q2 and Q3 2026, including BlackRock, State Street, Goldman Sachs, and Vanguard, signaling confidence in the franchise's value.
Bear case
  • Dyne Therapeutics' z-rostudirsen, targeting the same exon 51 DMD population, received FDA priority review with a PDUFA date of January 21, 2027. Citi noted z-rostudirsen could differentiate on higher efficacy and less frequent dosing, posing a direct competitive threat to EXONDYS 51's market share.
  • EXONDYS 51 was approved under accelerated approval based on a surrogate endpoint (dystrophin production), and confirmatory data have faced scrutiny. The drug has not been granted traditional FDA approval, leaving regulatory risk if confirmatory trials fail to demonstrate clinical benefit.
  • Analyst consensus on SRPT is mixed (12 buy/strong buy, 13 hold, 6 sell/strong sell) with a mean price target of $21.64, implying only ~21% upside from the $17.82 close. HC Wainwright reiterated a Sell rating with a $5 target in October 2026.
● neutral
Impact
PhasePhase 1/2
Time to marketAt least 4-6 years away, assuming successful completion of ongoing Phase 1/2 studies, advancement to registrational trials (likely Phase 2/3), and subsequent FDA review. No registrational trial design or timeline has been announced.

SRP-1001 Updated Nov 8

What to watch

Watch for Sarepta's next update on SRP-1001's Phase 1/2 MAD study, likely in 2027, which could inform the design of a registrational trial. The Q3 2026 earnings call indicated the FSHD and DM1 siRNA programs are being advanced toward registrational studies, but no specific timeline has been given. Positive data would validate the Arrowhead-acquired siRNA platform; negative data or delays would further pressure a stock already down over 75% from five-year highs amid Elevidys safety concerns.

Bull case
  • Initial Phase 1/2 data from March 2026 showed dose-dependent muscle exposure, early biomarker effects, and favorable tolerability with no dose-limiting toxicity, supporting the αvβ6 integrin-targeted siRNA delivery platform.
  • Sarepta is advancing SRP-1001 and its sister program SRP-1003 (DM1) toward registrational studies, per the Q3 2026 earnings call, signaling confidence in the platform.
  • The siRNA platform was acquired via a licensing deal with Arrowhead Pharmaceuticals, leveraging Arrowhead's proven RNAi technology with Sarepta's muscle disease expertise.
Bear case
  • SRP-1001 is still in early Phase 1/2 testing with no registrational trial design or timeline announced, meaning clinical and regulatory risk remains high.
  • Sarepta faces significant company-level headwinds: Elevidys (its approved Duchenne gene therapy) saw three patient deaths in the ENVISION trial, leading to trial closure and FDA scrutiny that has severely damaged management credibility and the stock.
  • Competition in FSHD is intensifying: Avidity Biosciences' delpacibart braxlosiran (del-brax/AOC 1020) is also targeting DUX4 in FSHD and has advanced further, pursuing a potential accelerated approval path with a biomarker cohort.

Other drugs in filings and trials

no drug report yet
  • VYONDYS 53 Last: Approval · Dec 12, 2019

Past FDA events & how the stock moved

8 events
DateDrugEvent1 day5 days
Apr 1, 2026AMONDYS 45NDA filed+6.8%+2.2%
Nov 1, 2025ELEVIDYSApproval+1.8%−26.6%
Nov 1, 2025ELEVIDYSPartial clinical hold+1.8%−26.6%
Jun 1, 2025ELEVIDYSClinical hold+0.4%+14.4%
May 1, 2025ELEVIDYSApproval+1.8%−41.5%
Feb 25, 2021AMONDYS 45Approval+3.3%−2.5%
Dec 12, 2019VYONDYS 53Approval+30.2%+23.5%
Sep 19, 2016EXONDYS 51Approval+98.0%+111.9%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
EXONDYS 51A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)Phase 3Completed160Sep 7, 2026